OBJECTIVE: The current standard treatment for ovarian carcinoma, consisting of surgery followed by chemotherapy with carboplatin and paclitaxel, is fraught with a high rate of recurrences. We hypothesized that targeted inhibition of specific signaling pathways in combination with conventional drugs may increase chemotherapeutic efficacy. METHODS: We analyzed the expression and activation profiles of various signaling pathways in nine established ovarian cancer cell lines (CAOV-3, ES2, PA-1, SKOV-3, NIHOVCAR3, OV90, TOV112D, A1847, A2780) and 24 freshly procured human ovarian tumors. The PI3 kinase pathway component Akt was frequently overexpressed and/or activated in tumor cells. The effect of several PI3K pathway inhibitors (rapamycin, LY294002, SH-6) and rapamycin in combination with carboplatin on various tumor cell growth characteristics was tested in cell lines and fresh tumor-derived transient monolayer and organ cultures. RESULTS: Rapamycin by itself and additively with carboplatin inhibited the growth and invasion, and increased the sensitivity to anoikis of most of the ovarian cancer cell lines and fresh tumors. The additive inhibitory effect may be due to enhanced apoptosis as demonstrated by Poly-ADP-Ribose Polymerase (PARP) cleavage and Annexin V staining in cells treated with both rapamycin and carboplatin. CONCLUSIONS: Rapamycin in combination with standard chemotherapeutic agents may improve the efficiency of ovarian cancer treatment.
OBJECTIVE: The current standard treatment for ovarian carcinoma, consisting of surgery followed by chemotherapy with carboplatin and paclitaxel, is fraught with a high rate of recurrences. We hypothesized that targeted inhibition of specific signaling pathways in combination with conventional drugs may increase chemotherapeutic efficacy. METHODS: We analyzed the expression and activation profiles of various signaling pathways in nine established ovarian cancer cell lines (CAOV-3, ES2, PA-1, SKOV-3, NIHOVCAR3, OV90, TOV112D, A1847, A2780) and 24 freshly procured humanovarian tumors. The PI3 kinase pathway component Akt was frequently overexpressed and/or activated in tumor cells. The effect of several PI3K pathway inhibitors (rapamycin, LY294002, SH-6) and rapamycin in combination with carboplatin on various tumor cell growth characteristics was tested in cell lines and fresh tumor-derived transient monolayer and organ cultures. RESULTS:Rapamycin by itself and additively with carboplatin inhibited the growth and invasion, and increased the sensitivity to anoikis of most of the ovarian cancer cell lines and fresh tumors. The additive inhibitory effect may be due to enhanced apoptosis as demonstrated by Poly-ADP-Ribose Polymerase (PARP) cleavage and Annexin V staining in cells treated with both rapamycin and carboplatin. CONCLUSIONS:Rapamycin in combination with standard chemotherapeutic agents may improve the efficiency of ovarian cancer treatment.
Authors: S M Ellerbroek; J M Halbleib; M Benavidez; J K Warmka; E V Wattenberg; M S Stack; L G Hudson Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: A J Philp; I G Campbell; C Leet; E Vincan; S P Rockman; R H Whitehead; R J Thomas; W A Phillips Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: Nandini Dey; Yuliang Sun; Jennifer H Carlson; Hui Wu; Xiaoqian Lin; Brian Leyland-Jones; Pradip De Journal: Am J Cancer Res Date: 2016-03-15 Impact factor: 6.166
Authors: Nandini Dey; Jennifer Aske; Xiaoqian Lin; Yuliang Sun; Brian Leyland-Jones; Lori Friedman; Pradip De Journal: Am J Cancer Res Date: 2021-06-15 Impact factor: 6.166
Authors: Zhuo Liu; Wook Kim; Zhike Chen; Yu-Kyong Shin; Olga D Carlson; Jennifer L Fiori; Li Xin; Joshua K Napora; Ryan Short; Juliana O Odetunde; Qizong Lao; Josephine M Egan Journal: PLoS One Date: 2011-01-25 Impact factor: 3.240
Authors: Ai Ling Liu; Hong Qing Liao; Zhi Liang Li; Jun Liu; Cui Lan Zhou; Zi Fen Guo; Hong Yan Xie; Cui Ying Peng Journal: Asian Pac J Cancer Prev Date: 2016-12-01